United States Chinese Anti-Cancer Association, is organized under the "general Not for Profit Corporation
Act" of the State of California, United States, exclusively for educational, scientific and charitable purposes.

The mission of the association is:

1、Facilitates collaborations among Chinese American professionals in the field of cancer research, treatment and prevention;

2、Promotes knowledge and information exchange between the professionals in the United States and China;

3、Provides educational information to serve cancer patients, their families, and the community.

The Latest News

2014 Chinese Clinical Oncology Advances Awards Announced

2014 Chinese Clinical Oncology Advances Awards Announced
From China Medical Tribune

USCACA sponsor - Chipscreen has its drug approved in China

Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China
SHENZHEN, China, Jan. 09, 2015 /PRNewswire/ -- Chipscreen Biosciences today announced regulatory approval of Chidamide (Epidaza®), the world first orally administrated and subtype-selective histone deacetylase (HDAC) inhibitor for relapsed or refractory peripheral T-cell lymphoma (PTCL) patients, in China on Dec. 23, 2014 by the Chinese Food and Drug Administration (CFDA).

International Collaboration Drives Discovery of Link Between Breast/Ovarian Cancer Gene and Stomach Cancer

BETHESDA, Md., Jan. 16, 2015 /PRNewswire-USNewswire/ -- A team of scientists from the United States and China has discovered new genetic insights that could change the way oncologists treat gastric cancer, the fourth most common cancer and the second leading cause of cancer death in the world. The investigators, who tested hundreds of gastric cancer tissue samples using advanced whole-genome sequencing technology, published their discovery online on January 12 in the Proceedings of National Academy of Sciences.

Sponsor and Partner